[18F]FES PET/.CT in Uterine Cancer

Recruiting Phase 2 Interventional Study
Uterine Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 2
Study type
Interventional
Purpose
Diagnostic
Participants needed
30 (estimated)
Sponsor
Abramson Cancer Center at Penn Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Women with known or suspected recurrent or metastatic uterine cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. \[18F\]fluoroestradiol (FES) PET/CT imaging will be used to evaluate estrogen receptor (ER) activity in areas of diseas…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria 1. Participants will be ≥ 18 years of age 2. Recurrent or metastatic or intact non-operated uterine cancer not treated with surgery that is biopsy-proven or demonstrated on other standard of care imaging (e.g. CT, FDG PET/CT, MRI, bone scan, x-ray, ultrasound) 3. At least one les…
Contacts

Erin o Schubert

2155736569

erin.schubert@pennmedicine.upenn.edu

CONTACT